HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Huda, Now Morphe Faces Proposed Nationwide Class Action Over Eyeshadow Colors

Executive Summary

A class action in California federal court targets Morphe Cosmetics for the sale and marketing of eyeshadows containing unapproved colors for eye-area use that three consumers say inflicted physical injury. They seek to represent consumers nationwide, citing breach of warranties, negligence, false advertising, and other claims.

You may also be interested in...

Huda Beauty To Settle Class Action Over Eyeshadows ‘Not Intended For The Eye Area'

US consumers who purchased Neon Obsession pressed pigment palettes may be entitled to refunds under a settlement preliminarily approved in California’s Central District. Plaintiffs say Huda promoted Neon Obsession as eyeshadow despite use of color additives not approved by the FDA for eye-area use, an issue that cannot be cured by a “buried” disclaimer on product packaging.

Beauty News In Brief: Estee Lauder’s Biotech Deal; Morphe Becomes FORMA Brands; More

Morphe Holdings has taken a new name, strengthened its leadership team and announced two new brand additions to its growing, multi-category beauty portfolio. Meanwhile, Lauder is partnering with Atropos Therapeutics to discover senomodulators with potential anti-aging benefits, and Fragrance Creators Association again successfully prevents tariffs on essential oil imports from the EU.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts